Rare copy number variants in treatment-resistant psychosis


Vignette’s case

“Mr. Hunter” is a 34-year-old African-American man with a historical past of continual schizophrenia and mental incapacity. He additionally has comorbid kind 2 diabetes and hypothyroidism. The onset of his psychosis was in his early teenagers. He has been clinically steady on clozapine for about 14 years, and has not been admitted to a psychiatric hospital throughout that point.

Mr. Hunter was adopted, and nothing is understood of his household’s psychobiological historical past. His adoptive mom died 7 years in the past, and his adoptive aunt grew to become his authorized guardian. His brief stature (top 154 cm) and a distinctly unsatisfactory face are famous for any widespread causes of mental incapacity. On a latest outpatient go to, his aunt inquired if his schizophrenia was brought on by “genetics”.

1 in 3 sufferers with psychosis develops treatment-resistant psychotic signs (TRS).1 These sufferers have higher cognitive deficits, impaired functioning, and suicide charges.2 Medical predictors of TRS are restricted.3 Current research of TRS sufferers have discovered an elevated burden of uncommon and deleterious copy quantity variants (CNVs).4,5 CNVs could inform concerning the organic mechanisms underlying therapy resistance.

The present examine

Farrell and colleagues6 investigated uncommon CNVs in a pattern of 509 sufferers with clinically confirmed TRS and in contrast the prevalence of schizophrenia-related CNVs on this pattern with a cohort not chosen for TRS.7 They recruited contributors from 5 Pennsylvania hospitals and their affiliated long-term structured residences. They included contributors underneath 18 years of age who have been ready and keen to present knowledgeable consent and who had been identified with schizophrenia, schizoaffective dysfunction, a temper dysfunction with psychotic options, or a psychotic dysfunction NOS. Members had steady psychotherapy for five years and no scientific enchancment regardless of ≥3 antipsychotic trials.

Exclusion standards have been psychosis associated to substance dependence, medical circumstances identified to trigger psychosis, and any sustained therapy response. Members have been clinically assessed utilizing the Constructive and Adverse Syndrome Scale (PANSS). Of the preliminary 690 contributors, 509 have been included within the remaining pattern.

DNA was extracted from the blood pattern and genome-wide SNP genotypes obtained from the Illumina Infinium World Screening Array. CNVs have been recognized from array density information utilizing 3 calling algorithms. High quality management steps have been used to take away low confidence CNV determinations. Exome sequencing information, utilizing the Agilent SureSelectXT Medical Analysis Exome, was out there for 478 contributors and used as one other method to establish CNV. CNVs are referenced with Listing of CNVs Related to Neurodevelopmental Issues.

The authors additionally in contrast the prevalence of (complete) schizophrenia CNVs of their pattern to a pattern of 21,094 contributors with schizophrenia who weren’t chosen for therapy resistance, utilizing a chi-square check. Loci-based comparisons of schizophrenia CNVs have been carried out between the 2 samples utilizing Fisher’s precise check, correcting for a number of comparisons.

The common age of the contributors was 52 years, 66% male and 75% white. The commonest diagnoses have been schizophrenia (47%) and schizoaffective dysfunction (46%). Among the many contributors, 51% have been uncovered to clozapine. Forty-seven of the 509 contributors (9.2%) had no less than 1 CNV probably related to scientific presentation; 24 (4.7%) 1 of the CNVs had neurodevelopmental danger, mostly a 16p11.2 repeat (n = 6), a 15q11.2–13.1 repeat (n = 4), and a 22q11.21 deletion (n = 4); And 21 of those 24 circumstances have been additionally carriers of different schizophrenia CNVs.

Eleven sufferers had a lot of CNVs (>1 Mb) not overlapping with a neurodevelopmental CNV or schizophrenia, and 12 sufferers had variants of unsure significance, mostly a 15q11.2 duplication (n = 4) and a 15q13.3 duplication (n = 4). n = 3). Members with CNVs had larger optimistic PANSS scores than non-carriers (21.0 vs 19.1). The prevalence of schizophrenia CNVs within the present examine (4.1%) was roughly twice as excessive as that within the pattern of contributors not chosen for therapy resistance (2.2%).

Examine conclusions

The authors discovered a 9.2% prevalence of level variations of neuropsychiatric illness danger in TRS circumstances. There was additionally an elevated prevalence of CNVs related to schizophrenia on this pattern. CNVs could contribute to common or particular dangers and outcomes in TRS. The genomic area 15q11.2-13.1, specifically, requires additional investigation. Whether or not extra widespread genetic testing in schizophrenia is warranted is an unresolved query. Strengths of this examine embrace the usage of a well-defined TRS equipment and a complete method to CNV detection.

backside line

Uncommon CNVs could affect scientific phenotypes and should function organic entry factors for the examine of treatment-resistant schizophrenia.

Dr. Miller Professor within the Division of Psychiatry and Well being Conduct at Augusta College in Augusta, Georgia. He’s a member of the editorial board and serves as chair of the schizophrenia division psychic occasionsTM. The creator studies that he’s receiving analysis assist from Augusta College, the Nationwide Institute of Psychological Well being, and the Stanley Institute of Medical Analysis.


1. Howes OD, McCutcheon R, Agid O, et al. Therapy-resistant schizophrenia: response to therapy and resistance to psychosis (TRRIP) Working Group Consensus Tips on Analysis and Terminology. I’m a psychiatrist. 2017; 174 (3): 216-229.

2. de Bartolomeis A, Balletta R, Giordano S et al. Differential cognitive efficiency between responders to schizophrenia and nonresponders to antipsychotics: associations with illness course, psychopathology, and angle to therapy and antipsychotic doses.. Res Psychiatry. 2013; 210 (2): 387-395.

3. Sensible SE, Kępińska AP, Murray RM, MacCabe JH. Predictors of treatment-resistant schizophrenia: a scientific evaluation of potential observational research. Psychol Med. 2021; 51 (1): 44-53.

4. Zoghbi AW, Dhindsa RS, Goldberg TE, et al. Uncommon high-impact genetic variants in extreme schizophrenia. Proc Natl Acad Sci USA. 2021; 118 (51): e2112560118.

5. Ruderfer DM, Charney AW, Readhead B, et al. Polygenic overlap between danger of schizophrenia and response to antipsychotics: a genomic drugs method. Lancet Psychiatry. 2016; 3 (4): 350-357.

6. Farrell M, Dietterich TE, Harner MK et al. Elevated prevalence of uncommon copy quantity variants in treatment-resistant psychosis [published online ahead of print, 2022 Dec 1]. Schizophrenia urine. 2022; sbac175.

7. Marshall Cr, Hourigan DB, Merico D, et al. Contribution of copy quantity variants to schizophrenia from a genome-wide examine of 41,321 topics. [published correction appears in Nat Genet. 2017 Mar 30;49(4):651] [published correction appears in Nat Genet. 2017 Sep 27;49(10):1558]. Nat Genet. 2017; 49 (1): 27-35.

Leave a Comment